Particular attention should be paid to other diabetes medications (especially insulin or sulfonylureas, which may require dose adjustment), and medications that affect gastric emptying
manufacturers of FDA-approved semaglutide and tirzepatide, and that "they do not sell these medications for compounding." The FDA has published safety concerns specifically about compounded and unapproved GLP-1 products, including reports of adverse events
Management Tips: Get plenty of rest and prioritise sleep
Patients should also seek immediate medical care if they experience severe, persistent abdominal pain (possibly radiating to the back) with or without vomiting, which could indicate pancreatitis
Metabolic effects : Tirzepatide addresses insulin resistance, glycemic control, and weight reduction, while sermorelin may influence metabolic processes through the GH-IGF-1 axis, though clinical significance remains unproven